Results 31 to 40 of about 5,935 (185)
Abciximab induced severe thrombocytopenia in an elderly patient [PDF]
Abciximab is a humanized monoclonal antibody which acts against αIIbβ3 receptor. The use of abciximab with percutaneous coronary interventions (PCI) has proven good results in patients.
Sen, Aastha +3 more
core +1 more source
The use of combination of fibrinolytic therapy and abciximab in the treatment of the acute myocardial infarction with ST elevation [PDF]
Background. According to current knowledge, the best way to treat the acute myocardial infarction with ST elevation is primary transluminal coronary angioplasty, which can be performed only in the best equipped tertiary cardiology centers.
Gligić Branko +4 more
doaj +1 more source
Intracoronary abciximab in STEMI using local drug delivery catheter – Single center experience
Background: Despite restoration of epicardial flow during primary PCI in STEMI, microvascular obstruction may persist as a result of both atheromatous and thrombotic embolization and vasospasm.
G. Sengottuvelu, V. Ravi Sekar
doaj +1 more source
1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention [PDF]
BACKGROUND: Diabetic patients are at increased risk for future cardiovascular events after ST-segment elevation myocardial infarction (STEMI). Administration of an intracoronary abciximab bolus during primary percutaneous coronary intervention (PCI) may
Eitel, Ingo +11 more
core +1 more source
Background Embolization of atherosclerotic debris from the rupture of a vulnerable atherosclerotic plaque occurs iatrogenically during percutaneous coronary interventions (PCI) and can induce myocardial necrosis.
Kretzschmar Daniel +9 more
doaj +1 more source
ABSTRACT Background Despite recommendations in international guidelines, Intracoronary pressure wire assessment (PWA) utilization remains limited in clinical practice. This study aims to describe (i) trends of PWA during Percutaneous coronary interventional (PCI), (ii) factors that predict its application, and (iii) association with in‐hospital ...
Hussein Bashar +3 more
wiley +1 more source
The use of abciximab associated with primary angioplasty for treating acute myocardial infarction
OBJECTIVE: To assess the benefit resulting from the use of abciximab associated with primary angioplasty. The following parameters were analyzed in-hospital, at 30 days, and 6 months: (a) flow in the culprit artery; (b) ventricular function; (c) combined
Manuel Lisandro Hernández Brito +6 more
doaj +1 more source
Lighting up αVβ6: Halotryptophan engineering converts an RGD scaffold into a modular αVβ6 ligand platform, enabling picomolar affinity and late‐stage functionalization. The resulting probes combine high selectivity with fluorescence for FACS and tumor imaging.
Beate Nachtigall +4 more
wiley +1 more source
Abstract Background Prekallikrein (PK) deficiency is a rare contact factor deficiency that can markedly prolong the activated partial thromboplastin time (aPTT) without a bleeding phenotype. Because viscoelastic hemostatic assays also rely on contact activation, their behavior in severe PK deficiency is relevant to perioperative evaluation of isolated ...
Jeremy W. Jacobs +7 more
wiley +1 more source
Background: Endovascular therapy and intravenous thrombolysis with recombinant tissue plasminogen activator are the 2 most recommended treatments for acute ischemic stroke (AIS). Glycoprotein (GP) IIb-IIIa inhibitors are short-acting selective reversible
Xiaolin Zhu MD, Genmao Cao MD
doaj +1 more source

